placeholder
Importance
78
Trust
71
Urgency
30
COMMERCIAL
Mounjaro Sales Exceed Keytruda in Q1 2026; Tirzepatide Sales Outpace Keytruda by $5 Billion in FY2025 - geneonline.com
Eli Lilly's tirzepatide (sold as Mounjaro for diabetes) brought in $5 billion more in sales than its cancer drug Keytruda in 2025. In early 2026, Mounjaro sales grew even larger and surpassed Keytruda's quarterly revenue.
Analysis
Lilly's tirzepatide is now its biggest drug, beating the old top seller Keytruda. This shows how huge the weight-loss and diabetes market has become.
- Tirzepatide sales beat Keytruda by $5 billion in 2025
- Mounjaro quarterly sales passed Keytruda in Q1 2026
- Mounjaro is Lilly's tirzepatide brand for diabetes
Tirzepatide News1mo
Read